We have conducted a multiwavelength survey of 42 radio loud narrow-1ine Seyfert 1 galaxies (RLNLS1s), selected by searching among all the known sources of this type and omitting those with steep ...radio spectra. We analyse data from radio frequencies to X-rays, and supplement these with information available from online catalogues and the literature in order to cover the full electromagnetic spectrum. This is the largest known multiwavelength survey for this type of source. We detected 90% of the sources in X-rays and found 17% at γ rays. Extreme variability at high energies was also found, down to timescales as short as hours. In some sources, dramatic spectral and flux changes suggest interplay between a relativistic jet and the accretion disk. The estimated masses of the central black holes are in the range ~106−8 M⊙, lower than those of blazars, while the accretion luminosities span a range from ~0.01 to ~0.49 times the Eddington limit, with an outlier at 0.003, similar to those of quasars. The distribution of the calculated jet power spans a range from ~1042.6 to ~1045.6 erg s-1, generally lower than quasars and BL Lac objects, but partially overlapping with the latter. Once normalised by the mass of the central black holes, the jet power of the three types of active galactic nuclei are consistent with each other, indicating that the jets are similar and the observational differences are due to scaling factors. Despite the observational differences, the central engine of RLNLS1s is apparently quite similar to that of blazars. The historical difficulties in finding radio-loud narrow-line Seyfert 1 galaxies might be due to their low power and to intermittent jetactivity.
Acute lymphoblastic leukemia (ALL) is the most common indication for transplantation of marrow from unrelated donors in children. We analyzed results of this procedure in children with ALL treated ...according to a standard protocol to determine risk factors for outcome. From January 1987 to 1999, 88 consecutively seen patients with ALL who were younger than 18 years received a marrow transplant from an HLA-matched (n = 56) or partly matched (n = 32) unrelated donor during first complete remission (CR1; n = 10), second remission (CR2; n = 34), third remission (CR3; n = 10), or relapse (n = 34). Patients received cyclophosphamide and fractionated total-body irradiation as conditioning treatment and were given methotrexate and cyclosporine for graft-versus-host disease (GVHD) prophylaxis. Three-year rates of leukemia-free survival (LFS) according to phase of disease were 70% for CR1, 46% for CR2, 20% for CR3, and 9% for relapse (P < .0001). Three-year cumulative relapse rates were 10%, 33%, 20%, and 50%, respectively, and 3-year cumulative rates of death not due to relapse were 20%, 22%, 60%, and 41%, respectively, for patients with CR1, CR2, CR3, and relapse. Grades III to IV acute GVHD occurred in 43% of patients given HLA-matched transplants and in 59% given partly matched transplants (P = .10); clinical extensive chronic GVHD occurred in 32% and 38%, respectively (P = .23). LFS rates were lower in patients with advanced disease (P < .0001), age 10 years or older (P = .002), or short duration of CR1 (P = .007). Thus, in addition to phase of disease, age and duration of CR1 were predictors of outcome after unrelated-donor transplantation for treatment of ALL in children. Outcome was particularly favorable in younger patients with early phases of the disease.
We present response and survival outcomes of a pivotal phase 2 trial of the antibody-drug conjugate brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma following autologous stem ...cell transplant (N = 102) after a median observation period of approximately 3 years. Median overall survival and progression-free survival were estimated at 40.5 months and 9.3 months, respectively. Improved outcomes were observed in patients who achieved a complete remission (CR) on brentuximab vedotin, with estimated 3-year overall survival and progression-free survival rates of 73% (95% confidence interval CI: 57%, 88%) and 58% (95% CI: 41%, 76%), respectively, in this group (medians not reached). Of the 34 patients who obtained CR, 16 (47%) remain progression-free after a median of 53.3 months (range, 29.0 to 56.2 months) of observation; 12 patients remain progression-free without a consolidative allogeneic stem cell transplant. Younger age, good performance status, and lower disease burden at baseline were characteristic of patients who achieved a CR and were favorable prognostic factors for overall survival. These results suggest that a significant proportion of patients who respond to brentuximab vedotin can achieve prolonged disease control. The trial was registered at www.clinicaltrials.gov as #NCT00848926.
•A total of 47% of patients who achieved CR on brentuximab vedotin remain progression-free after being followed a median of 53 months.•Younger age, less functional impairment, and lower disease burden at baseline were associated with CR and prognostic for longer survival.
Abstract
We present cosmological constraints based on the cosmic microwave background (CMB) lensing potential power spectrum measurement from the recent 500 deg
2
SPTpol
survey, the most precise CMB ...lensing measurement from the ground to date. We fit a flat ΛCDM model to the reconstructed lensing power spectrum alone and in addition with other data sets: baryon acoustic oscillations (BAO), as well as primary CMB spectra from
Planck
and
SPTpol
. The cosmological constraints based on
SPTpol
and
Planck
lensing band powers are in good agreement when analyzed alone and in combination with
Planck
full-sky primary CMB data. With weak priors on the baryon density and other parameters, the
SPTpol
CMB lensing data alone provide a 4% constraint on
. Jointly fitting with BAO data, we find
,
, and
, up to
away from the central values preferred by
Planck
lensing + BAO. However, we recover good agreement between
SPTpol
and
Planck
when restricting the analysis to similar scales. We also consider single-parameter extensions to the flat ΛCDM model. The
SPTpol
lensing spectrum constrains the spatial curvature to be
and the sum of the neutrino masses to be
eV at 95% C.L. (with
Planck
primary CMB and BAO data), in good agreement with the
Planck
lensing results. With the differences in the signal-to-noise ratio of the lensing modes and the angular scales covered in the lensing spectra, this analysis represents an important independent check on the full-sky
Planck
lensing measurement.
Abstract
We present a measurement of the cosmic microwave background lensing potential using 500 deg
2
of 150 GHz data from the SPTpol receiver on the South Pole Telescope. The lensing potential is ...reconstructed with signal-to-noise per mode greater than unity at lensing multipoles
L
≲ 250, using a quadratic estimator on a combination of cosmic microwave background temperature and polarization maps. We report measurements of the lensing potential power spectrum in the multipole range of 100 <
L
< 2000 from sets of temperature-only (
T
), polarization-only (POL), and minimum-variance (MV) estimators. We measure the lensing amplitude by taking the ratio of the measured spectrum to the expected spectrum from the best-fit Λ cold dark matter model to the
Planck
2015 TT + low
P
+ lensing data set. For the minimum-variance estimator, we find
A
MV
=
0.944
±
0.058
(
Stat
.
)
±
0.025
(
Sys
.
)
;
restricting to only polarization data, we find
A
POL
=
0.906
±
0.090
(
Stat
.
)
±
0.040
(
Sys
.
)
. Considering statistical uncertainties alone, this is the most precise polarization-only lensing amplitude constraint to date (10.1
σ
) and is more precise than our temperature-only constraint. We perform null tests and consistency checks and find no evidence for significant contamination.
Recent observations support the hypothesis that a large fraction of 'short-hard' gamma-ray bursts (SHBs) are associated with the inspiral and merger of compact binaries. Since gravitational-wave (GW) ...measurements of well-localized inspiraling binaries can measure absolute source distances, simultaneous observation of a binary's GWs and SHB would allow us to directly and independently determine both the binary's luminosity distance and its redshift. Such a 'standard siren' (the GW analog of a standard candle) would provide an excellent probe of the nearby (z 0.3) universe's expansion, independent of the cosmological distance ladder, thereby complementing other standard candles. Previous work explored this idea using a simplified formalism to study measurement by advanced GW detector networks, incorporating a high signal-to-noise ratio limit to describe the probability distribution for measured parameters. In this paper, we eliminate this simplification, constructing distributions with a Markov Chain Monte Carlo technique. We assume that each SHB observation gives source sky position and time of coalescence, and we take non-spinning binary neutron star and black hole-neutron star coalescences as plausible SHB progenitors. We examine how well parameters (particularly distance) can be measured from GW observations of SHBs by a range of ground-based detector networks. We find that earlier estimates overstate how well distances can be measured, even at fairly large signal-to-noise ratio. The fundamental limitation to determining distance proves to be a degeneracy between distance and source inclination. Overcoming this limitation requires that we either break this degeneracy, or measure enough sources to broadly sample the inclination distribution.
ABSTRACT The Atacama Cosmology Telescope (ACT) makes high angular resolution measurements of anisotropies in the Cosmic Microwave Background (CMB) at millimeter wavelengths. We describe ACTPol, an ...upgraded receiver for ACT, which uses feedhorn-coupled, polarization-sensitive detector arrays, a 3° field of view, 100 mK cryogenics with continuous cooling, and meta material antireflection coatings. ACTPol comprises three arrays with separate cryogenic optics: two arrays at a central frequency of 148 GHz and one array operating simultaneously at both 97 GHz and 148 GHz. The combined instrument sensitivity, angular resolution, and sky coverage are optimized for measuring angular power spectra, clusters via the thermal Sunyaev-Zel'dovich (SZ) and kinetic SZ signals, and CMB lensing due to large-scale structure. The receiver was commissioned with its first 148 GHz array in 2013, observed with both 148 GHz arrays in 2014, and has recently completed its first full season of operations with the full suite of three arrays. This paper provides an overview of the design and initial performance of the receiver and related systems.
In this study, we determined whether fibrin glue improves cell transplant retention and survival, reduces infarct expansion, and induces neovasculature formation.
Current efforts in restoring the ...myocardium after myocardial infarction (MI) include the delivery of viable cells to replace necrotic cardiomyocytes. Cellular transplantation techniques are, however, limited by transplanted cell retention and survival within the ischemic tissue.
The left coronary artery of rats was occluded for 17 min followed by reperfusion. One week later, bovine serum albumin (BSA), fibrin glue, skeletal myoblasts in BSA, or skeletal myoblasts in fibrin glue were injected into the infarcted area of the left ventricle. The animals were euthanized five weeks after injection, and their hearts were excised, fresh frozen, and sectioned for histology and immunohistochemistry.
After five weeks, the mean area covered by skeletal myoblasts in fibrin glue was significantly greater than the area covered by myoblasts injected in BSA. Myoblasts within the infarct were often concentrated around arterioles. The infarct scar size and myoblasts in the fibrin group were significantly smaller than those in the control and BSA groups. Fibrin glue also significantly increased the arteriole density in the infarct scar as compared with the control group.
This study indicates that fibrin glue increases cell transplant survival, decreases infarct size, and increases blood flow to ischemic myocardium. Therefore, fibrin glue may have potential as a biomaterial scaffold to improve cellular cardiomyoplasty treat and MIs.
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults and accounts for 20% of pediatric leukemia. Although conventional chemotherapy induces clinical remissions in most ...patients with AML, recurrent leukemia represents the major obstacle to cure. Conventional chemotherapy reinduction is associated with limited efficacy and substantial toxicity. Chemotherapy specifically targeted to leukemic cells by monoclonal antibodies might enable patients to achieve remissions more safely than conventional approaches. After evaluating a series of phase II studies, the U.S. Food and Drug Administration approved Mylotarg (gemtuzumab ozogamicin) for the treatment of patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered candidates for other types of cytotoxic chemotherapy. Among 277 adult patients with CD33-positive AML in first relapse, 26% experienced an overall response after Mylotarg monotherapy. Despite the fact that myelosuppression, hyperbilirubinemia, and elevated hepatic transaminases were commonly observed, the incidences of severe infections and mucositis were relatively low in comparison with conventional chemotherapeutic treatment. Preliminary reports in pediatric patients also report Mylotarg to be reasonably well tolerated. Recently, data from study regimens combining Mylotarg and conventional chemotherapy suggest an unusually high remission induction rate in de novo AML patients. Information assembled from prospective, ongoing studies in the United States and the United Kingdom should help us use this novel immunoconjugate in a safe and effective manner.
Acromegaly is a rare disorder caused by chronic growth hormone (GH) hypersecretion. While diagnostic and therapeutic methods have advanced, little information exists on trends in acromegaly ...characteristics over time. The
, a relational database, is designed to assess the profile of acromegaly patients at diagnosis and during long-term follow-up at multiple treatment centers. The following results were obtained at diagnosis. The study population consisted of 3173 acromegaly patients from ten countries; 54.5% were female. Males were significantly younger at diagnosis than females (43.5 vs 46.4 years;
< 0.001). The median delay from first symptoms to diagnosis was 2 years longer in females (
= 0.015). Ages at diagnosis and first symptoms increased significantly over time (
< 0.001). Tumors were larger in males than females (
< 0.001); tumor size and invasion were inversely related to patient age (
< 0.001). Random GH at diagnosis correlated with nadir GH levels during OGTT (
< 0.001). GH was inversely related to age in both sexes (
< 0.001). Diabetes mellitus was present in 27.5%, hypertension in 28.8%, sleep apnea syndrome in 25.5% and cardiac hypertrophy in 15.5%. Serious cardiovascular outcomes like stroke, heart failure and myocardial infarction were present in <5% at diagnosis. Erythrocyte levels were increased and correlated with IGF-1 values. Thyroid nodules were frequent (34.0%); 820 patients had colonoscopy at diagnosis and 13% had polyps. Osteoporosis was present at diagnosis in 12.3% and 0.6-4.4% had experienced a fracture. In conclusion, this study of >3100 patients is the largest international acromegaly database and shows clinically relevant trends in the characteristics of acromegaly at diagnosis.
PDF
